News
HepaRegeniX plans to use the proceeds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, the company’s lead clinical candidate in liver regeneration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback